secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0001683168-23-002542
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio raises ~$2M in registered direct offering with warrants, amends existing warrants
--------------------------------------------------------------------------------

- Issued 353,983 shares at $5.65/share, gross proceeds ~$2.0M; net ~$1.65M after fees.
- Concurrent private placement: Series A (5.5-yr) and Series B (18-mo) warrants for up to 707,966 shares at $5.40.
- Amended 191,619 existing warrants from exercise prices $26.52–$2,079.00 down to $5.40 for $0.125 each.
- Net proceeds for immuno-oncology development, working capital, and general corporate purposes.
- Offering closed April 20, 2023; H.C. Wainwright acted as exclusive placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/0001683168-23-002542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823002542/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-002542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer